<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501657</url>
  </required_header>
  <id_info>
    <org_study_id>061025</org_study_id>
    <nct_id>NCT00501657</nct_id>
  </id_info>
  <brief_title>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</brief_title>
  <official_title>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Adelaide Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Adelaide Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate&#xD;
      at which the stomach empties, and the release of gut hormones and blood glucose&#xD;
      concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to&#xD;
      reduce the blood glucose (sugar) response to a meal and this may potentially be due to&#xD;
      slowing of stomach emptying. This is particularly relevant to people who have diabetes, in&#xD;
      whom normalization of elevated blood glucose levels is important to maintain health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying,&#xD;
      intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects.&#xD;
      Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of&#xD;
      nutrients, and their absorption, across the small intestine. The rate of entry of&#xD;
      carbohydrate into the small intestine is especially important in patients with diabetes&#xD;
      mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV&#xD;
      (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that&#xD;
      sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and&#xD;
      diminish the glycemic response to, a carbohydrate-containing meal.&#xD;
&#xD;
      Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on&#xD;
      two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching&#xD;
      placebo in a randomized, double blind, crossover design. Measurements of gastric emptying,&#xD;
      intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will&#xD;
      be measured for 4 hours following ingestion of a mashed potato meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying rate</measure>
    <time_frame>4 hours per study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite</measure>
    <time_frame>4 hours per study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin (100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive drug (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg mane for 2 days</description>
    <arm_group_label>Sitagliptin (100mg)</arm_group_label>
    <other_name>MK-0431-075</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mg mane for 2 days</description>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (females must be using an appropriate contraceptive method)&#xD;
&#xD;
          -  18 - 45 years&#xD;
&#xD;
          -  Body mass index (BMI) 19 - 25 kg/m2.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or&#xD;
             significant gastrointestinal symptoms&#xD;
&#xD;
          -  Subjects taking medication known to influence gastrointestinal function&#xD;
&#xD;
          -  Alcohol intake &gt; 20 g per day&#xD;
&#xD;
          -  Smoking &gt; 10 cigarettes per day&#xD;
&#xD;
          -  Pregnant and/or lactating females&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  Exposure to ionising radiation for research purposes in the previous 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Adelaide, Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Discipline of Medicine, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22738299</url>
    <description>Pubmed abstract</description>
  </link>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Adelaide Hospital</investigator_affiliation>
    <investigator_full_name>Karen Jones</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric emptying</keyword>
  <keyword>glycemia</keyword>
  <keyword>appetite</keyword>
  <keyword>incretin hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

